Save time and jump to the most important pieces.
The Glinka family invested $4.5 million into Nutriband through the Company's April 2024 private placementORLANDO, FL / ACCESSWIRE / May 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, today announced the appointment of Sergei Glinka to its board of directors. Glinka is a seasoned and highly respected business executive with an impressive track record in leadership roles across major European companies.Mr. Glinka, an Estonian citizen, is an experienced and highly regarded businessman who has held numerous Executive and Board positions in large European Companies providing Glinka with deep insights and networks across various industri
8-K - NutriBand Inc. (0001676047) (Filer)
8-K - NutriBand Inc. (0001676047) (Filer)
10-Q - NutriBand Inc. (0001676047) (Filer)
5 - NutriBand Inc. (0001676047) (Issuer)
5 - NutriBand Inc. (0001676047) (Issuer)
5 - NutriBand Inc. (0001676047) (Issuer)
ORLANDO, FL / ACCESSWIRE / October 31, 2024 / Nutriband (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that theChinese National Intellectual Property Administrant (CNIPA) has fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology AVERSA™.The patent underpins 4p Therapeutics' abuse deterrent transdermal system, AVERSA, which uses taste aversion to address the primary routes of abuse for opioid based transdermal patches. The patent number reflects the issuance of Patent No: ZL 202211158031.The CNIPA issued a prior notice of allowance in September 2024.About AVERSA™ Abuse-Deterrent Transdermal TechnologyNutriband's AVERSA™ ab
ORLANDO, FL / ACCESSWIRE / October 2, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is pleased to invite investors to a webinar on October 17, 2024, at 4:15 p.m. ET.The exclusive event, hosted by RedChip Companies, will feature Nutriband Founder and Chief Executive Officer Gareth Sheridan and Founder and President Serguei Melnik, who will share insight into the Company's current operations and upcoming milestones. Nutriband stands at the forefront of addressing the global opioid crisis with its revolutionary AVERSA™ abuse-deterrent transdermal technology. The Company's lead product, AVERSA™ Fentanyl, is targeting peak annual sales of
Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technologyNutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch productsAVERSA Fentanyl has the potential to be the world's first and only abuse-deterrent opioid patchORLANDO, FL / ACCESSWIRE / September 24, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today
Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) fell sharply during Wednesday's session after the company reported first-quarter financial results. Bolt Biotherapeutics posted a GAAP loss of 28 cents per share on sales of $5.30 million, according to data from Benzinga Pro. Also, Guggenheim analyst Michael Schmidt downgraded Bolt Biotherapeutics from Buy to Neutral, while Stifel analyst Stephen Willey downgraded the stock from Buy to Hold and lowered the price target from $6 to $1.5. Bolt Biotherapeutics shares dipped 34.4% to $0.8652 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers AERWINS Technologies Inc. (NASDAQ:AWIN) shares surged
SC 13D/A - NutriBand Inc. (0001676047) (Subject)
SC 13G - NutriBand Inc. (0001676047) (Subject)
SC 13G - NutriBand Inc. (0001676047) (Subject)
ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Can-Fite: https://www.redchip.com/assets/access/canf_accessNutriband: https://www.redchip.com/assets/access/ntrb_accessIn an exclusive interview, Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, appears on the RedChip Small Stocks, Big Money™ show on Blo
Nutriband among the first issuers to dual list on UpstreamORLANDO, FL / ACCESSWIRE / January 5, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, will become available today at 10:00am EST under the ticker symbol NTRB on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ"). Nutriband's digital collectible NFT commemorating the dual listing is also available for all Upstream participants to claim with the claim code "NTRB!".Global investors can now trade by downloading Upstream from their preferred app sto
Trading scheduled to Commence on Upstream January 5, 2023ORLANDO, FL / ACCESSWIRE / December 30, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today that it will be the first company to dual list on Upstream following recent approval."We are proud to have a trailblazer like Nutriband as the first company to dual list on Upstream and offer its shares to an international investor-base seeking streamlined access to U.S. companies," says Upstream Co-Founder Mark Elenowitz.The dual listing on Upstream is designed to provide Nutriband the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, u